摘要
棘阿米巴(Acanthamoeba)是一类分布广泛、侵入人体后可引起严重、甚至致命感染的机会致病性寄生原虫。药物治疗仍是目前棘阿米巴感染首选的治疗方法。但滋养体抗药性的产生及药物治疗过程中滋养体可转变为休眠形式的抗药性包囊,导致感染复发,使治疗十分困难。近年来,传统药物不断改进,新型药物持续研发,为棘阿米巴感染的精准、高效治疗提供了广阔前景。该文概述抗棘阿米巴药物如抗细菌类药物、抗真菌药物、双胍类和新型制剂(如纳米粒子和树枝状大分子)等的研究现状,以期为棘阿米巴感染的有效治疗提供参考,为新型药物的研发提供思路。
Acanthamoeba is an opportunistic protozoa that is widely distributed in the natural environments and can cause serious,even fatal infections after invading the human body.At present,drug therapy is still the first choice of treatment.However,the drug-resistant trophozoites and cysts that are changed from trophozoites cause the recurrence of infection,and it has also become a problematic challenge to treat.With the development of science and technology,traditional medicine is improved,and novel drugs continue to be developed that provide broad prospects for the accurate and efficient drug treatment of Acanthamoeba infection.This paper focuses on the research status of anti-acanthamoeba drugs in recent years,which reviewed from four aspects:antibacterial drugs,antifungal drugs,biguanides,and new preparations(nanoparticles and dendrimers),in order to guide the effective treatment of Acanthamoeba infection and ideas for the development of new drugs.
作者
王月华
鞠晓红
WANG Yuehua;JU Xiaohong(Laboratory Institute,Jilin Medical University,Jilin 132013,China)
出处
《医药导报》
CAS
北大核心
2023年第9期1363-1367,共5页
Herald of Medicine
基金
吉林省教育厅基金资助项目(JJKH2021-0489KJ)。
